Oryzon receives approval to begin REIMAGINE: a Phase IIa clinical trial with Vafidemstat (ORY-2001) in aggressiveness

7 September 2018 MADRID, SPAIN and CAMBRIDGE MA. • The approval has been granted by the Spanish Medicines Agency • The study will be done in patients with 3 psychiatric disorders and 2 neurodegenerative disorders • This is the first Phase IIa study with Vafidemstat (ORY-2001) in the psychiatric field Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today the approval by the Spanish Medicines Agency (AEMPS) of a clinical trial authorization (CTA) to carry out a Phase IIa trial with Vafidemstat (ORY-2001) in patients with episodes of aggressiveness. Click here to see the full Press Release

The release as fetched from its publisher. oryzon.com ↗